Transforming patients’ lives today and tomorrow¹
Enbrel® is a TNFi approved for treating multiple chronic diseases in rheumatology and dermatology.2
Heritage of Enbrel®
Approved by the EMA in 2000,6 Enbrel® was the first-approved TNFi in RA.1
Enbrel® is approved across 6 therapeutic indications, including paediatric indications.²
The efficacy and safety profile of Enbrel® has been established across
What type of patients may be the best candidates for Enbrel® therapy?
Patient access to Enbrel® starts with a complex and highly controlled manufacturing process.14,15
The Capital – A Wing, 1802, 18th Floor, Plot
No. C-70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051, India.
®Trademark Proprietor – Wyeth LLC, USA
Licensed User – Pfizer Limited, India
To view the summary of prescribing
information for ENBREL®, please
For the use only of Registered Medical
Practitioners or a Hospital or a Laboratory.
Full prescribing information available on
*Some studies may have evaluated (or will evaluate) etanercept biosimilars and/or evaluated (or will evaluate) indications for which Enbrel® is not approved.
EMA, European Medicines Agency; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022